Aspire Biopharma (ASBP) Competitors

$5.87 +0.57 (+10.75%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$5.68 -0.19 (-3.24%)

As of 05:49 AM Eastern

ASBP vs. VIVS, REVB, IOBT, GLMD, and ALBT

Should you buy Aspire Biopharma stock or one of its competitors? MarketBeat compares Aspire Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aspire Biopharma include VivoSim Labs (VIVS), Revelation Biosciences (REVB), IO Biotech (IOBT), Galmed Pharmaceuticals (GLMD), and Avalon GloboCare (ALBT). These companies are all part of the "pharmaceutical products" industry.

How does Aspire Biopharma compare to VivoSim Labs?

Aspire Biopharma (NASDAQ:ASBP) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

VivoSim Labs has higher revenue and earnings than Aspire Biopharma. VivoSim Labs is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	99.79	-$24.48M	-$20.00	N/A
VivoSim Labs	$140K	24.61	-$2.48M	-$3.15	N/A

In the previous week, Aspire Biopharma had 2 more articles in the media than VivoSim Labs. MarketBeat recorded 5 mentions for Aspire Biopharma and 3 mentions for VivoSim Labs. VivoSim Labs' average media sentiment score of 0.44 beat Aspire Biopharma's score of -0.26 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aspire Biopharma has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Aspire Biopharma has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. Aspire Biopharma's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-1,468.13%
VivoSim Labs	-861.27%	-15.51%	-11.31%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Aspire Biopharma beats VivoSim Labs on 7 of the 13 factors compared between the two stocks.

How does Aspire Biopharma compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Revelation Biosciences has higher earnings, but lower revenue than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A
Aspire Biopharma	$10K	99.79	-$24.48M	-$20.00	N/A

Aspire Biopharma's return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-107.65%	-87.98%
Aspire Biopharma	N/A	N/A	-1,468.13%

Revelation Biosciences has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

In the previous week, Revelation Biosciences had 2 more articles in the media than Aspire Biopharma. MarketBeat recorded 7 mentions for Revelation Biosciences and 5 mentions for Aspire Biopharma. Revelation Biosciences' average media sentiment score of 0.44 beat Aspire Biopharma's score of -0.26 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revelation Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 8.0% of Revelation Biosciences shares are held by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Revelation Biosciences beats Aspire Biopharma on 6 of the 11 factors compared between the two stocks.

How does Aspire Biopharma compare to IO Biotech?

Aspire Biopharma (NASDAQ:ASBP) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Aspire Biopharma had 3 more articles in the media than IO Biotech. MarketBeat recorded 5 mentions for Aspire Biopharma and 2 mentions for IO Biotech. IO Biotech's average media sentiment score of 0.00 beat Aspire Biopharma's score of -0.26 indicating that IO Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
IO Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aspire Biopharma has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, IO Biotech has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Aspire Biopharma has higher revenue and earnings than IO Biotech. Aspire Biopharma is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	99.79	-$24.48M	-$20.00	N/A
IO Biotech	N/A	N/A	-$95.49M	-$1.35	N/A

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 54.8% of IO Biotech shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by insiders. Comparatively, 2.3% of IO Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

IO Biotech has a consensus price target of $3.50, indicating a potential upside of 7,191.67%. Given IO Biotech's stronger consensus rating and higher possible upside, analysts clearly believe IO Biotech is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IO Biotech	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Aspire Biopharma's return on equity of 0.00% beat IO Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-1,468.13%
IO Biotech	N/A	-517.22%	-200.69%

Summary

IO Biotech beats Aspire Biopharma on 8 of the 13 factors compared between the two stocks.

How does Aspire Biopharma compare to Galmed Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

In the previous week, Aspire Biopharma had 2 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 5 mentions for Aspire Biopharma and 3 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.96 beat Aspire Biopharma's score of -0.26 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aspire Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Galmed Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

Galmed Pharmaceuticals has higher earnings, but lower revenue than Aspire Biopharma. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
Aspire Biopharma	$10K	99.79	-$24.48M	-$20.00	N/A

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aspire Biopharma's return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%
Aspire Biopharma	N/A	N/A	-1,468.13%

Summary

Galmed Pharmaceuticals beats Aspire Biopharma on 7 of the 11 factors compared between the two stocks.

How does Aspire Biopharma compare to Avalon GloboCare?

Aspire Biopharma (NASDAQ:ASBP) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Avalon GloboCare has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	99.79	-$24.48M	-$20.00	N/A
Avalon GloboCare	$1.26M	2.29	-$18.26M	-$3.51	N/A

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 24.2% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aspire Biopharma has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Avalon GloboCare has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

In the previous week, Aspire Biopharma had 2 more articles in the media than Avalon GloboCare. MarketBeat recorded 5 mentions for Aspire Biopharma and 3 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 1.42 beat Aspire Biopharma's score of -0.26 indicating that Avalon GloboCare is being referred to more favorably in the news media.

Company	Overall Sentiment
Aspire Biopharma	Neutral
Avalon GloboCare	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-1,468.13%
Avalon GloboCare	N/A	N/A	-74.36%

Summary

Avalon GloboCare beats Aspire Biopharma on 7 of the 11 factors compared between the two stocks.

Get Aspire Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASBP vs. The Competition

Export

Metric	Aspire Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$890K	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.29	18.47	20.66	25.63
Price / Sales	99.79	294.84	545.69	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	-0.11	6.93	9.94	6.97
Net Income	-$24.48M	$24.11M	$3.55B	$333.62M
7 Day Performance	3,072.97%	5.89%	1.69%	1.09%
1 Month Performance	-64.09%	-0.91%	0.48%	3.08%
1 Year Performance	N/A	74.58%	39.38%	35.68%

Aspire Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASBP Aspire Biopharma	0.2075 of 5 stars	$5.87 +10.8%	N/A	N/A	$890K	$10K	N/A	N/A	Stock Split Short Interest Increase Gap Down
VIVS VivoSim Labs	0.5783 of 5 stars	$1.39 -1.4%	N/A	N/A	$3.63M	$140K	N/A	20	News Coverage Short Interest Increase
REVB Revelation Biosciences	1.218 of 5 stars	$0.96 -5.9%	N/A	-97.3%	$3.57M	N/A	N/A	10	Analyst Downgrade Analyst Revision High Trading Volume
IOBT IO Biotech	2.4837 of 5 stars	$0.05 flat	$3.50 +7,191.7%	N/A	$3.45M	N/A	N/A	30
GLMD Galmed Pharmaceuticals	1.5576 of 5 stars	$0.61 -2.5%	N/A	-49.7%	$3.35M	N/A	N/A	20	News Coverage Upcoming Earnings Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASBP) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aspire Biopharma (ASBP) Competitors

ASBP vs. VIVS, REVB, IOBT, GLMD, and ALBT

How does Aspire Biopharma compare to VivoSim Labs?

Summary

How does Aspire Biopharma compare to Revelation Biosciences?

Summary

How does Aspire Biopharma compare to IO Biotech?

Summary

How does Aspire Biopharma compare to Galmed Pharmaceuticals?

Summary

How does Aspire Biopharma compare to Avalon GloboCare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aspire Biopharma (ASBP) Competitors

ASBP vs. VIVS, REVB, IOBT, GLMD, and ALBT

How does Aspire Biopharma compare to VivoSim Labs?

Do insiders & institutionals believe in ASBP or VIVS?

Which has better valuation and earnings, ASBP or VIVS?

Does the media refer more to ASBP or VIVS?

Which has more volatility and risk, ASBP or VIVS?

Is ASBP or VIVS more profitable?

Do analysts rate ASBP or VIVS?

Summary

How does Aspire Biopharma compare to Revelation Biosciences?

Which has better valuation and earnings, REVB or ASBP?

Is REVB or ASBP more profitable?

Which has more volatility and risk, REVB or ASBP?

Does the media prefer REVB or ASBP?

Do insiders and institutionals believe in REVB or ASBP?

Do analysts prefer REVB or ASBP?

Summary

How does Aspire Biopharma compare to IO Biotech?

Does the media favor ASBP or IOBT?

Which has more risk & volatility, ASBP or IOBT?

Which has preferable earnings and valuation, ASBP or IOBT?

Do insiders & institutionals have more ownership in ASBP or IOBT?

Do analysts rate ASBP or IOBT?

Is ASBP or IOBT more profitable?

Summary

How does Aspire Biopharma compare to Galmed Pharmaceuticals?

Does the media prefer GLMD or ASBP?

Which has more risk & volatility, GLMD or ASBP?

Which has higher valuation and earnings, GLMD or ASBP?

Do institutionals & insiders have more ownership in GLMD or ASBP?

Do analysts prefer GLMD or ASBP?

Is GLMD or ASBP more profitable?

Summary

How does Aspire Biopharma compare to Avalon GloboCare?

Which has better valuation and earnings, ASBP or ALBT?

Do insiders and institutionals hold more shares of ASBP or ALBT?

Which has more volatility & risk, ASBP or ALBT?

Does the media favor ASBP or ALBT?

Do analysts recommend ASBP or ALBT?

Is ASBP or ALBT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools